ArticleFrontiers in medicine2026
Multidimensional effects of the Xin'an Jianpi Tongbi Formula on self-perception of patients with rheumatoid arthritis: focusing on the mediating role of systemic inflammation index.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the effects of the Xin'an Jianpi Tongbi Formula (XAJPF), composed mainly of Huangqin Qingre Chubi Capsule (HQC) and Xinfeng Capsule (XFC), on the systemic inflammation and self-perception of patients (SPP) composite outcomes in rheumatoid arthritis (RA), and innovatively analyze the mediating effect of systemic inflammation index. Methods: This retrospective cohort study was conducted in the Department of Rheumatology of the First Affiliated Hospital of Anhui University of Chinese Medicine from August 2023 to February 2025. The study used admission and discharge as primary time points, grouping 935 RA patients based on their baseline median neutrophil-to-lymphocyte ratio (NLR) levels and employing propensity score matching to control for intergroup confounders. Exposure was defined as receiving XAJPF treatment (divided into high/low exposure groups based on the type). Multimodal analyses, including logistic regression, association rules, mediation analysis, and sensitivity analysis, were used to comprehensively evaluate the effects of XAJPF on the primary outcomes (SPP scores) and secondary outcomes [NLR and systemic inflammation response index (SIRI)]. Results: After matching, baseline characteristics were balanced between groups. Higher inflammatory status was associated with worse SPP scores. Compared with the non-exposure group, XAJPF exposure demonstrated superior efficacy in improving SPP outcomes and systemic inflammation levels, without causing hepatic or renal injury. Multivariable-adjusted logistic regression identified XAJPF as an independent protective factor against worsening PF, GH, VT, MH, VAS, PGA, PhGA, CPRI-RA, SDS, SDH, and SDSSD, with odds ratios of 0.24, 0.60, 0.54, 0.50, 0.44, 0.46, 0.54, 0.56, 0.43, 0.29, and 0.49 (all Conclusion: This study establishes the pivotal role of NLR and SIRI in the inflammation-perception axis of RA and confirms them as partial mediators of the multidimensional therapeutic effects of XAJPF. This provides a novel perspective for understanding the clinical application of the Chinese compound.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.